中文字幕理论片,69视频免费在线观看,亚洲成人app,国产1级毛片,刘涛最大尺度戏视频,欧美亚洲美女视频,2021韩国美女仙女屋vip视频

李健斌，江澤飛

軍事醫(yī)學研究院生物工程研究所

解放軍總醫(yī)院第五醫(yī)學中心　　

　　基于循證醫(yī)學證據(jù)、兼顧診療產品的可及性、吸收精準醫(yī)學新進展是中國臨床腫瘤學會指南制定的首要標準。結合這樣的標準，在2018版中國臨床腫瘤學會乳腺癌指南的基礎上，結合臨床研究進展，融入真實世界數(shù)據(jù)，結合臨床實踐經(jīng)驗，更新形成了2019年中國臨床腫瘤學會乳腺癌指南。新版指南對乳腺癌新輔助治療、輔助治療、解救治療、治療管理做了較大幅度修改，同時新增了液體活檢、二代測序、人工智能等新章節(jié)，更加全面的指導乳腺癌臨床工作。該文對2019年中國臨床腫瘤學會乳腺癌指南更新要點作解讀。

通訊作者：江澤飛，jiangzefei@csco.org.cn

原文參見：中國腫瘤外科雜志. 2019;11(3):155-160.

相關閱讀

• 中國抗癌協(xié)會乳腺癌診治指南與規(guī)范（2019年版）

參考文獻

1. Broglio KR, Quintana M, Foster M, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2016;2(6):751-760.

2. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017;376(22):2147-2159.

3. Buzdar AU, Suman VJ, Meric-Bernstam F, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised. controlled. phase 3 trial. Lancet Oncol. 2013;14(13):1317-1325.

4. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced. inflammatory. or early-stage HER2-positive breast cancer (NeoSphere): a multicentre. open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791-800.

5. Curigliano G, Burstein HJ, P Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700-1712.

6. Sparano JA, Gray RJ, Makower DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015;373(21):2005-2014.

7. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121.

8. Cardoso F, van't VLJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016;375(8):717-729.

9. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122-131.

10. von MG, Huang cs. Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628.

11. Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre. randomised. double-blind, placebo-controlled. phase 3 trial. Lancet Oncol. 2016;17(3):367-377.

12. Chen L, Zhou W, Hu X, et al. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials. Cancer Treat Rev. 2019;75:12-19.

13. Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2019;37(22):1868-1875.

14. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122-137.

15. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27(2):3611-3619.

16. Zhang P, Sun T, Zhang Q, et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncol. 2017;18(3):371-383.

17. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108-2121.

18. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline brca mutation. N Engl J Med. 2017;377(6):523-533.

19. Blair HA. Pyrotinib: First Global Approval. Drugs, 2018;78(16):1751-1755.

20. Swain SM, Baselga J, Kim SB, et al. Pertuzumab. trastuzumab. and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-734.

21. Li J, Wang S, Wang Y, et al. Disparities of trastuzumab use in resource-limited or resource-abundant regions and its survival benefit on HER2 positive breast cancer: a real-world study from China. Oncologist. 2017;22(11):1333-1338.

22. JFR R, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised. double-blind, phase 3 trial. Lancet. 2016;388(10063):2997-3005.

23. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.

24. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre. double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439.

25. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915.

26. Jiang Z, Li W, Hu X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(6):806-815.

27. Yang LQ, Sun XC, Qin SK, et al. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized. double-blind, phase III study. Chin Clin Oncol. 2016;5(6):79.

28. 江澤飛, 許鳳銳, 樊菁, 等. 聚乙二醇化重組人粒細胞刺激因子預防乳腺癌患者化療后中性粒細胞減少的多中心隨機對照Ⅳ期臨床觀察. 中華醫(yī)學雜志. 2018;98(16):1231-1235.

29. 李健斌, 江澤飛. 循環(huán)腫瘤細胞研究進展：從計數(shù)到表型的轉變. 中華腫瘤雜志. 2016;38(12):881-885.

30. 葉青, 江澤飛. 循環(huán)腫瘤DNA檢測在乳腺癌診斷中的臨床應用. 中國癌癥雜志. 2016;26(11):947-951.

31. 江澤飛, 許鳳銳. 腫瘤醫(yī)生眼中的人工智能. 精準醫(yī)學雜志. 2018;33(1):9-11,14.

32. 江澤飛, 李峰, 許鳳銳. 腫瘤智能決策：熱潮中的冷思考. 中華外科雜志. 2019;57(2):85-87.